AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 582772
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg WE 941
Trial: 582772
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg flurazepam
Trial: 11525594
Drug: Fresh broccoli
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh broccoli (200 g)
Trial: 11525594
Drug: Steamed broccoli
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steamed broccoli (200 g)
Trial: 8288160
Drug: Dexfenfluramine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexfenfluramine (15 mg twice daily for 8 days)
Trial: 24332524
Drug: Oligofructose-enriched inulin
RxNorm normalized name: Inulin
DrugBank: Inulin (DB00638)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oligofructose-enriched inulin (10 g/d)
Trial: 24332524
Drug: Maltodextrin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltodextrin (10 g/d)
Trial: 21877913
Drug: Basal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal insulin monotherapy (n=27)
Trial: 21877913
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous insulin infusion (CSII) (n=32)
Trial: 19164492
Drug: Extended-release bupropion
RxNorm normalized name: bupropion Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release bupropion (150-300 mg once daily)
Trial: 16389916
Drug: Test drug
RxNorm normalized name: URINE TEST DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test drug
Trial: 12362231
Drug: Oral E(2)
RxNorm normalized name: Aquasol E Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral E(2) 1 mg (oE(2) group, n = 37)
Trial: 12362231
Drug: Oral E(2)
RxNorm normalized name: Aquasol E Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral E(2) 1 mg combined with gestodene 25 micro g (oE(2) + G group, n = 33)
Trial: 12362231
Drug: Transdermal 17beta‐oestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17beta‐oestradiol (E(2)) 50 micro g (tE(2) group, n = 33)
Trial: 1309390
Drug: 0.1 ml
RxNorm normalized name: ethanol 0.1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 ml of iodized oil (47 mg of iodine)
Trial: 1309390
Drug: 0.25 ml
RxNorm normalized name: mineral oil 0.25 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 ml of iodized oil (118 mg of iodine)
Trial: 31780001
Drug: Nasal spray
RxNorm normalized name: Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal spray containing IND02 (100 μg/100 μL), twice a day for seven days
Trial: 26985911
Drug: Adherent interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adherent interventions to the Clinical Treatment Algorithm (CTA)
Trial: 26985911
Drug: Nonadherent interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonadherent interventions to the Clinical Treatment Algorithm (CTA)
Trial: 25468575
Drug: Warmed i-gel
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warmed i-gel (42°C for 30 minutes)
Trial: 25468575
Drug: Room temperature
RxNorm normalized name: ROOM DEODORIZER POWDER MENTOR #3202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Room temperature i-gel (approximately 23°C)
Trial: 19333160
Drug: Placebo (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral water)
Trial: 7038189
Drug: Cefroxadine (CXD)
RxNorm normalized name: cefradine
DrugBank: Cefroxadine (DB11367)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefroxadine (CXD) at doses of 5, 10, and 20 mg/kg
Trial: 26949924
Drug: Psychoeducation text
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducation text focusing on medication
Trial: 26949924
Drug: Psychoeducation text
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducation text focusing on psychodynamic therapy
Trial: 20412274
Drug: Rosiglitazone 4
RxNorm normalized name: rosiglitazone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone 4 mg twice daily for 4 months
Trial: 20412274
Drug: Pioglitazone 30
RxNorm normalized name: pioglitazone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 30 mg daily for 4 months
Trial: 16277141
Drug: Treatment optimism
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment optimism
Trial: 28342943
Drug: Antipsychotics for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotics for schizophrenia
Trial: 28342943
Drug: Perceived treatability
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perceived treatability and belief in effectiveness of treatment for schizophrenia
Trial: 28342943
Drug: Perceived treatability
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perceived treatability and belief in effectiveness of treatment for depression
Trial: 26651484
Drug: Behavior change
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavior change strategy consisting of one individual theoretical counseling session plus eight twice-a-week individual theoretical and practical exercise counseling sessions for 3 years.
Trial: 26651484
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care including general physician recommendations for daily PA.
Trial: 19036671
Drug: Vancomycin 2
RxNorm normalized name: vancomycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin 2 g/day (1 g intravenously twice daily) and Aztreonam 4 g/day (2 g intravenously twice daily)
Trial: 16609033
Drug: High LET
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High LET carbon beam therapy
Trial: 8929043
Drug: Ketorolac infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac infusion (150 mg in 60 ml isotonic chlorinated solution at 0.5 ml/h + 4 bolus/h of 0.5 ml)
Trial: 8929043
Drug: Morphine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine infusion (60 ml in 60 ml isotonic chlorinated solution at the same rate)
Trial: 8929043
Drug: Placebo (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (60 ml isotonic chlorinated solution + Ketorolac intramuscular on demand)
Trial: 6375805
Drug: Cicloxolone cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cicloxolone cream
Trial: 6375805
Drug: Carbenoxolone cream
RxNorm normalized name: carbenoxolone
DrugBank: Carbenoxolone (DB02329)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbenoxolone cream
Trial: 30219432
Drug: Psyllium (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psyllium (10 g pre-mixed in cookies twice per day for 12 weeks)
Trial: 22500643
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment at Waiyingxiang (LI 20)
Trial: 20605871
Drug: CPB with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPB with low tidal volume ventilation (3 ml.kg(‐1)) without positive end expiratory pressure (PEEP)
Trial: 17433950
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of enalaprilat
Trial: 11971197
Drug: New treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New treatment schedule of melarsoprol (10 daily doses of 2.16 mg/kg)
Trial: 11971197
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment protocol of melarsoprol (3 series of 3-4 injections every 24 hours)
Trial: 11971197
Drug: New treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New treatment schedule of melarsoprol
Trial: 11971197
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment protocol of melarsoprol
Trial: 12914803
Drug: Group cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive therapy
Trial: 1972434
Drug: Indomethacin (0.1‐0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (0.1‐0.2 mg/kg) administered by rapid injection (30 s)
Trial: 1972434
Drug: Indomethacin (0.1‐0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (0.1‐0.2 mg/kg) administered by slow infusion (20‐30 min)
Trial: 29127080
Drug: 24 mg
RxNorm normalized name: uracil 224 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 mg ENDS
Trial: 29127080
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg ENDS
Trial: 31086287
Drug: 1.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg rhCC10
Trial: 31086287
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg rhCC10
Trial: 10211913
Drug: Zatosetron 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zatosetron 0.2 mg
Trial: 10211913
Drug: Zatosetron 1
RxNorm normalized name: alosetron 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zatosetron 1 mg
Trial: 10211913
Drug: Zatosetron 5
RxNorm normalized name: alosetron 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zatosetron 5 mg
Trial: 7789938
Drug: McCanse Readiness
FDA approved: no
EMA approved: no
PMDA approved: no
Description: McCanse Readiness for Death Instrument (MRDI) administered to terminally-ill individuals
Trial: 7789938
Drug: McCanse Readiness
FDA approved: no
EMA approved: no
PMDA approved: no
Description: McCanse Readiness for Death Instrument (MRDI) administered to cardiac-impaired individuals (control group)
Trial: 354312
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of calcium per day
Trial: 21977379
Drug: Rivastigmine patch
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine patch (9.5 mg/24-h)
Trial: 24434526
Drug: Rivastigmine capsules
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine capsules (12 mg/d)
Trial: 19122080
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of normal saline solution at a rate of 5 mL/sec through an 18-gauge needle at the inferomedial location
Trial: 19122080
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of normal saline solution at a rate of 5 mL/sec through an 18-gauge needle at the superomedial location
Trial: 19122080
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of normal saline solution to diagnose 50% of arthrotomies
Trial: 19122080
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of normal saline solution to diagnose 75% of arthrotomies
Trial: 19122080
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of normal saline solution to diagnose 90% of arthrotomies
Trial: 19122080
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of normal saline solution to diagnose 95% of arthrotomies
Trial: 19122080
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of normal saline solution to diagnose 99% of arthrotomies
Trial: 17222324
Drug: Hydroxyzine 25
RxNorm normalized name: hydroxyzine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyzine 25 mg at bedtime
Trial: 15605774
Drug: Karinat (antioxidant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Karinat (antioxidant dietary supplement)
Trial: 9786536
Drug: Sublingual hyoscyamine
RxNorm normalized name: hyoscyamine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual hyoscyamine sulfate (0.125 mg)
Trial: 9786536
Drug: Intravenous ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketorolac tromethamine (30 mg)
Trial: 7602722
Drug: Diet supplemented
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet supplemented with 20 g of soluble fiber (partially hydrolyzed guar gum, Sunfiber)
Trial: 27819483
Drug: Music listening
RxNorm normalized name: Listerine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music listening (ML) (n = 54)
Trial: 18338278
Drug: TENS therapy
RxNorm normalized name: Walgreens Electronic TENS Therapy Pain Relief Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TENS therapy (20 minutes, 15 sessions over 3 weeks)
Trial: 9683949
Drug: Intravenous teicoplanin
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous teicoplanin (5 patients each at 1 h, 12 h, 24 h pre-operatively, and 24 h and 48 h pre-operatively)
Trial: 9683949
Drug: Topical teicoplanin
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical teicoplanin drops (5 patients, half-hourly for 6 h before vitrectomy)
Trial: 24702251
Drug: Hydralazine (83
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydralazine (83 mg for slow acetylators, 182 mg for fast acetylators)
Trial: 24702251
Drug: Valproate (700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valproate (700 mg every 8 hours)
Trial: 17008798
Drug: Active EECP
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active EECP therapy
Trial: 16120091
Drug: HMR 1031
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMR 1031 (20 mg b.i.d.)
Trial: 9451475
Drug: Pravastatin, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin, 20 mg/day
Trial: 3131256
Drug: Fat infusion
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fat infusion (1.2 g fat/kg B.W./day)
Trial: 26749228
Drug: Gabapentin (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (1200 mg, 600 mg 8 hours before and 600 mg 2 hours before anesthesia induction)
Trial: 24255597
Drug: Micronutrient supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient supplement (Perfectil® Platinum)
Trial: 21804509
Drug: Oral levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral levofloxacin 750mg once daily for 7 days
Trial: 21804509
Drug: Injectable levofloxacin
RxNorm normalized name: levofloxacin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable levofloxacin 500mg once daily for 7 days
Trial: 16452280
Drug: Collaborative care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative care (medication and counseling for up to 12 months)
Trial: 16452280
Drug: Receipt of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receipt of preferred treatment
Trial: 15265539
Drug: Good oral
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Good oral hygiene
Trial: 9002119
Drug: Oral ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ciprofloxacin alone (Group I)
Trial: 9002119
Drug: Ciprofloxacin plus
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin plus inhaled amikacin (Group II)
Trial: 31399540
Drug: Combined perineural
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined perineural dexmedetomidine (1 µg/kg) and dexamethasone (10 mg) in 2 mL (RSM group)
Trial: 31399540
Drug: Perineural dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Perineural dexamethasone (10 mg) in 2 mL (RS group)
Trial: 31399540
Drug: Perineural dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perineural dexmedetomidine (1 µg/kg) in 2 mL (RM group)
Trial: 26466937
Drug: Risedronate (48-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate (48-week treatment)
Trial: 22572234
Drug: Intermittent bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent bolus injection of 0.375% ropivacaine into intrapleural space (IPA group, n = 20)
Trial: 17053894
Drug: Bread meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bread meal before itraconazole administration
Trial: 17053894
Drug: Rice meal
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice meal before itraconazole administration
Trial: 10376571
Drug: Raloxifene, 60
RxNorm normalized name: Raloxifene, 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene, 60 mg, 2 tablets daily
Trial: 8629721
Drug: New treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New treatment (specific details not provided)
Trial: 8629721
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (specific details not provided)
Trial: 1381330
Drug: Combaren (diclofenac-Na
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combaren (diclofenac-Na 50 mg + codeine phosphate 50 mg)
Trial: 1381330
Drug: diclofenac-Na 50
RxNorm normalized name: diclofenac sodium 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diclofenac-Na 50 mg (Voltaren 50)
Trial: 6421009
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg ISDN (acute administration)
Trial: 6421009
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg ISDN (chronic treatment, four doses daily)
Trial: 6421009
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg ISDN (acute administration)
Trial: 6421009
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg ISDN (long-term treatment, twice daily)
Trial: 6421009
Drug: 0.8 mg
RxNorm normalized name: biotin 0.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mg NTG (sublingual during treatment with 40 mg ISDN)
Trial: 30248052
Drug: Antipsychotics, citalopram,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotics, citalopram, or placebo (duration: up to 36 weeks, mean 252±52 days)
Trial: 25023458
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with therapeutic apheresis and haemopheresis with Albutein® and intravenous immunoglobulin (Flebogamma® DIF)
Trial: 23405791
Drug: Compound Xuanju
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Xuanju Capsule (CXC) at 3 g tid plus sildenafil at 50 mg an hour before sexual activity
Trial: 23405791
Drug: Sildenafil alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil alone at 100 mg an hour before sexual activity
Trial: 19093205
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of Taiproton (generic lansoprazole)
Trial: 19093205
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of Tapizol (generic lansoprazole)
Trial: 19093205
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of Lansoral (generic lansoprazole)
Trial: 9594519
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural injection of buprenorphine (0.2 mg) with 0.25% bupivacaine (40 ml) for 24 hours (Group A)
Trial: 9594519
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of buprenorphine (0.2 mg) followed by continuous injection of buprenorphine (0.2 mg) with 0.25% bupivacaine (40 ml) for 24 hours (Group B)
Trial: 9594519
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of buprenorphine (0.2 mg) followed by continuous buprenorphine infusion with normal saline (Group C)
Trial: 9594519
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural injection of buprenorphine (Group C)
Trial: 8207739
Drug: Ro 42-5892
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 42-5892 (100 mg once daily orally)
Trial: 8207739
Drug: Ro 42-5892
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 42-5892 (10 mg intravenously)
Trial: 2530925
Drug: 75 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 micrograms fentanyl with 12 ml of 0.25% plain bupivacaine
Trial: 2530925
Drug: 15 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 micrograms sufentanil with 12 ml of 0.25% plain bupivacaine